Best objective response according to MGR
| Discovery cohort n (%) | Confirmation cohort n (%) | Validation cohort n (%) | |||||||
| PD | SD | PR/CR | PD | SD | PR/CR | PD | SD | PR/CR | |
| MGR ≤3.9 mm/month | 4 (14) | 9 (32) | 15 (54) | 23 (31) | 13 (17) | 39 (52) | 18 (19) | 23 (24) | 53 (56) |
| MGR >3.9 mm/month | 21 (84) | 1 (4) | 3 (12) | 32 (70) | 3 (7) | 11 (24) | 30 (47) | 11 (17) | 23 (36) |
| OR*: 28.4 (5.9 to 187.5) p<0.0001 | OR: 5.1 (2.2 to 12.5) p<0.0001 | OR: 3.7 (1.7 to 8.1) p=0.00036 | |||||||
Best objective response was assessed according to Response Evaluation Criteria in Solid Tumors V.1.1.
*ORs and p values were determined utilizing two-sided Fisher’s exact test comparing PD versus SD/PR/CR.
CR, complete response; MGR, metastatic growth rate; PD, progressive disease; PR, partial response; SD, stable disease.